Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Description:

For complete study information, please visit clinicaltrials.gov

Study Status:
Closed
Study Sponsor:

Vertex Pharmaceuticals Incorporated

Full IRB Study Title:
A Phase 2, Randomized, Double‑blind, Controlled Study to Evaluate the Safety of VX‑152 Combination Therapy in Adults With Cystic Fibrosis Protocol: VX16-152-102
IRB Study ID:
968803-8
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Gregory Omlor, MD, FAAP

Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.